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Background : Pulmonary hypertension (PH) related to autoimmune hemolytic anemia (AIHA) is still rarely 
discussed, and there is a paucity of literature regarding its precise pathophysiology and treatment. 
Objective : We aimed to describe a case of PH associated with AIHA. 
Case : A 34-year-old woman came to our emergency department with a chief complaint of dyspnea on exertion. 
She was previously diagnosed with AIHA with a positive direct Coomb's test. Group 5 pulmonary hypertension 
was established after findings from physical examination, chest X-ray, and echocardiography were consistent 
with pulmonary hypertension. Although it was rare, it was believed that the association between chronic 
hemolytic anemia and PH is occurred through several mechanisms involving nitric oxide inactivation, direct 
injury of the endothelium, oxidative damage, thromboembolic formation, and left ventricular dysfunction. The 
treatment of underlying hemolytic disorder and PH-specific therapies were done as the management of PH in 
hemolytic disorders. For PH-specific therapy, to date, no treatment has been comprehensively studied for these 
specific patient populations. Our patient was given bisoprolol, furosemide, amlodipine, spironolactone, candesar-
tan, beraprost sodium, and sildenafil. On a two-month follow-up, her functional status was improved. 
Conclusion : In summary, PH in AIHA could be detected with meticulous history taking, physical examination, 
chest X-ray and echocardiography, and treatment with vasodilating agents were shown to improve the PH.
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 Resting mean pulmonary artery pressure (mPAP) sustained 
above 25 mmHg is defined as Pulmonary hypertension (PH). It can be 
caused by a primary elevation of pressure in the pulmonary artery or 
secondary to pressure elevation in the pulmonary venous and capillary 
systems.1 The incidence was reported around 10-52 cases per million.2 
This disease is rare but can be progressive and fatal, especially if it is 
undetected and untreated. The one-year mortality rate after diagnosis 
ranges from 2,8-21,2%, varying among different etiologies of PH.3
 PH has been described to associate with hemolytic anemia, 
including group 5 PH. The prevalence of PH in patient with hemolytic 
anemia was estimated to be as high as 10-40%, and several reports 
presented poor prognosis of PH in this subset of patients. One of the 
common forms of hemolytic anemia is autoimmune hemolytic anemia 
(AIHA). However, PH associated with AIHA is rarely discussed, and 
there is a paucity of literature in its precise pathophysiology and 
treatment. Here we described a case of PH associated with AIHA.
2. Case Presentation
 A 34-year-old woman came to our hospital with chief 
complaint of dyspnea on exertion (WHO functional class III) and 
abdominal bloating. She was previously diagnosed AIHA with positive 
direct Coomb's test. Vital signs examination revealed normal result; the 
blood pressure was 130/80 mmHg, heart rate was 80 bpm, and respira-
tory rate was 18x/mins. On physical examination, we found a raised 
JVP, loud S2 with accentuation of pulmonary component, and holosys-
tolic murmur on the tricuspid area. The peripheral saturation was 98% 
on room air. 12-lead ECG revealed sinus rhythm with incomplete RBBB 
and fragmented QRS in inferior leads.
 Chest X-ray showed an inverted comma sign, pruning of 
peripheral pulmonary vessel, and prominent pulmonary outflow tract. 
Echocardiography showed dilated RA and RV, normal left ventricular 
function with LVEF 67.7% (Teich), normal LV diastolic function (E/A 
value 1.13), and normal right ventricular function with TAPSE 3.17 cm. 
We also found severe tricuspid regurgitation with TR Vmax 4.69 m/s 
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and pressure gradient 87.9 mmHg (figure 1) and decreased PVACCT 
(99 msec), consistent with pulmonary hypertension. The LV was also 
D-shaped, indicating that right ventricular pressure exceeded the left 
ventricular pressure. No other cardiac structural abnormality was found 
on echocardiography. The diagnosis of group 5 PH was established (due  
to chronic hemolytic anemia). She was then given bisoprolol 2,5 mg od, 
furosemide 40 mg od, amlodipine 5 mg od, spironolactone 25 mg od, 
candesartan 8 mg od, dorner (beraprost sodium) 10 mcg bid, and 
sildenafil 12,5 mg bid. On two-months follow up, her functional status 
was improved. She was able to perform ordinary physical activity 
without any symptoms (WHO functional class I-II).  
3. Discussion
  Pulmonary hypertension (PH) is an increase in mPAP of 25 
mmHg or higher at rest, confirmed by right heart catheterization 
(RHC). In clinical practice, it is usually diagnosed by echocardiography, 
using the velocity of tricuspid regurgitation jet to estimate the pressure 
of the pulmonary artery although the gold standard of PH diagnosis is 
by RHC. WHO classifies PH into five groups. Group 1 PH (pulmonary 
arterial hypertension) most commonly has an idiopathic causes. It may 
be also caused by drug, human immunodeficiency virus, or congenital 
heart defect. Group 2 PH is caused by left-sided heart disease, such as 
mitral or aortic valve disease, or left ventricular dysfunction. Group 3 
PH is caused by chronic respiratory disorders such as chronic obstruc-
tive pulmonary disorder (COPD) or interstitial pulmonary fibrosis. 
Group 4 PH is caused by chronic thromboembolism. Group 5 PH 
comprises PH with unclear or multifactorial causes, such as in hemato-
logic disorder as found in our patient.4,5
 Evaluation of PH may be conducted through several modali-
ties, including history taking, physical examination, echocardiography, 
and RHC for the gold standard. From history and physical examination, 
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Figure 1. Echocardiography of the patient showing severe TR, with TR Vmax of 4.69 m/s and peak gradient of 87.9 mmHg.
PH can be asymptomatic, but it is often associated with exertional 
dyspnea or fatigue. Hemoptysis, angina, presyncope, and syncope 
suggest severe disease. Physical examination may reveal a parasternal  
lift, tricuspid regurgitation murmur, widely split S2 in the absence of 
RBBB/ASD, and pulmonary ejection sound.6 Loud pulmonary compo-
nent of the second heart sound, as found in our patient, reflects an 
increase in pulmonary artery pressure.
 In PH, echocardiography evaluation would demonstrate 
elevated tricuspid regurgitation peak velocity that suggests elevated 
right ventricular systolic pressure.7 From echocardiography of our 
patient, no right ventricular hypertrophy was found. Although, the size 
of the right atrium and the right ventricle were increased. Our patient 
had TAPSE of 3.17 cm, indicating normal RV function. However, the LV 
was found to be D-shaped, suggesting that the RV pressure exceeded LV 
pressure. Severe TR and decreased PVACCT were found in our patient, 
indicating elevated pulmonary pressure.
 PH has been associated with hemolytic anemia, including 
group 5 PH. One of the common forms of hemolytic anemia is AIHA. In 
AIHA, it was known that antibodies against self-antigens on red blood 
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cells (RBC) membrane causing a shortened RBC lifespan. RBC will be 
coated by antibodies; then, a macrophage will bind to them via their Fc 
receptor, digesting them with proteolytic enzyme, and causing the RBC 
to be spherical and more susceptible to osmotic lysis. This lysis may 
occur both in intravascular and extravascular. Furthermore, attachment 
of other antibodies such as IgG1, IgG3, IgM, and IgA can fix the comple-
ment, causing intravascular hemolysis.8 
 The pathways that lead hemolytic anemia to PH are multifac-
torial, involving a reduction in nitric oxide (NO), dysregulation of 
arginine metabolism, endothelial injury, hypercoagulability, thrombo-
embolic formation, and left ventricular dysfunction (figure 2).
 In hemolysis, the breakdown of erythrocyte will release 
hemoglobin and arginase enzyme into circulation. Cell-free hemoglobin 
can inactivate NO. NO is a substance that maintains vasodilation by 
activating cGMP-dependent protein kinases, inhibiting platelet aggrega-
tion and attachment, and reducing adhesion molecules such as vascular 
cell adhesion molecule and the potent vasoconstrictor endothelin-1. In 
addition, arginase enzyme, released from erythrocyte, can convert 
arginine to ornithine, while arginine is the substrate for NO synthesis, 
thereby decreasing the substrate for NO production. The conversion of 
arginine to ornithine also produces proline and polyamines, which can 
increase vascular smooth muscle proliferation and cause production 
and deposition of collagen. All these changes would result in pulmonary 
vascular endothelium remodeling and vasoconstriction.9 Hemoglobin 
can also impair endothelial function via direct cytotoxic and pro-oxi-
dant effects.10
 The hypercoagulable state associated with an inflammatory 
state in hemolytic anemia has also been shown to contribute to the 
development of PH through endothelial dysfunction and thromboem-
bolic formation.9 Hemolysis may also cause activation of tissue factor 
by formation of RBC microvesicles expressing phosphatidylserine, 
which increase the risk of thrombosis. 
 Hemolysis is also associated with decreased systemic 
resistance (due to a decrease in viscosity), causing high output cardiac 
failure. This condition will cause activation of the neurohormonal 
system leading to cardiac remodeling in heart failure. This cardiac 
remodeling will cause left heart disease, causing increased end-diastolic 
pressure, congestion of pulmonary vein, and PH.11 However, in our 
patient, the LV diastolic function was still normal, suggesting that 
cardiac remodeling might not have occurred.
 The treatment of underlying hemolytic disorder and PH-spe-
cific therapies were done as part of pH management in hemolytic 
disorders. Corticosteroids are the first-line treatment for AIHA by 
reducing the autoimmune activity.10 For the PH-specific therapy (such 
as prostacyclin antagonist, soluble guanylate cyclase stimulators, and 
phosphodiesterase-5 inhibitors, and endothelin receptor antagonist,), 
no treatment was studied and approved by FDA for these specific 
populations.12
 Our patient was treated with bisoprolol (to prevent right 
heart failure), furosemide (to relieve congestion), amlodipine (to 
manage the BP), spironolactone, candesartan (to manage BP and 
prevent myocardial remodeling), beraprost sodium (vasodilator), and
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Figure 2. Mechanism of pulmonary hypertension in hemolytic anemia. The association between chronic hemolytic anemia and PH is evident, 
through several mechanisms involving nitric oxide inactivation, proliferation of vascular smooth muscle, collagen deposition, direct injury of the 
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sildenafil  (vasodilator).13 These treatments were shown to improve the 
functional status of the patient. As explained before, in a patient with 
AIHA, reduction in NO, the free hemoglobin, and other oxidative 
damage may cause endothelial dysfunction and vasoconstriction, 
therefore vasodilating agents may cause improvement as found in our 
patient.
4. Conclussion
 PH associated AIHA develop via multifactorial and complex 
mechanisms, and the data regarding the pathophysiology and manage-
ment are limited. In our case, we inferred that PH in AIHA could be 
detected with meticulous history taking, physical examination, chest 
X-ray and echocardiography, and treatment with vasodilating agents 
such as beraprost and sildenafil were shown to improve the PH.
5. Declarations
5.1. Ethics Approval and Consent to participate 
Patient has provided informed consent prior to involve in the study.
5.2. Consent for publication
Not applicable.
5.3. Availability of data and materials
Data used in our study were presented in the main text.
5.4. Competing interests
Not applicable.
5.5. Funding source
Not applicable.
5.6. Authors contributions 
Idea/concept: MDHQ. Design: MDHQ. Control/supervision: MHDQ. 
Data collection/processing: MDHQ, HA. Extraction/Analysis/interpre-
tation: MDHQ, HA. Literature review: HA. Writing the article: MDHQ, 
HA. Critical review: MDHQ, HA. All authors have critically reviewed 
and approved the final draft and are responsible for the content and 
similarity index of the manuscript.
5.7. Acknowledgements
We thank to Brawijaya Cardiovascular Research Center.
References
35
Örem C. Epidemiology of pulmonary hypertension in the elderly. J 
Geriatr Cardiol 2017;14(1):11-6.
Hoeper MM, Simon R. Gibbs J. The changing landscape of 
pulmonary arterial hypertension and implications for patient care. 
European Respiratory Review 2014;23:450-7.
Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary 
arterial hypertension: prediction by the 2015 European pulmonary 
hypertension guidelines risk stratification model. European 
Respiratory Journal 2017;50:1700740.
Wijeratne DT, Lajkosz K, Brogly SB, et al. Increasing incidence and 
prevalence of World Health Organization groups 1 to 4 pulmonary 
hypertension: a population-based cohort study in Ontario, Canada. 
Circulation: Cardiovascular Quality and Outcomes 
2018;11:e003973.
Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald 
E. Braunwald E. Braunwald's Heart Disease: A Textbook of Cardio-
vascular Medicine. 11th ed. Canada: Elsevier; 2019:4316.
1.
2.
3.
4.
5.
Örem C. Epidemiology of pulmonary hypertension in the elderly. J 
Geriatr Cardiol 2017;14(1):11-6.
Hoeper MM, Simon R. Gibbs J. The changing landscape of pulmo-
nary arterial hypertension and implications for patient care. 
European Respiratory Review 2014;23:450-7.
Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial 
hypertension: prediction by the 2015 European pulmonary 
hypertension guidelines risk stratification model. European Respira-
tory Journal 2017;50:1700740.
Wijeratne DT, Lajkosz K, Brogly SB, et al. Increasing incidence and 
prevalence of World Health Organization groups 1 to 4 pulmonary 
hypertension: a population-based cohort study in Ontario, Canada. 
Circulation: Cardiovascular Quality and Outcomes 
2018;11:e003973.
Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald 
E. Braunwald E. Braunwald's Heart Disease: A Textbook of Cardio-
vascular Medicine. 11th ed. Canada: Elsevier; 2019:4316.
Opotowsky AR. Clinical evaluation and management of pulmonary 
hypertension in the adult with congenital heart disease. Circulation 
2015;131:200-10.
Augustine DX, Coates-Bradshaw LD, Willis J, et al. Echocardio-
graphic assessment of pulmonary hypertension: a guideline 
protocol from the British Society of Echocardiography. Echo 
research and practice 2018;5(3):G11-G24.
Hoffman R, Benz EJ, Shattil SJ, et al. Hematology Basic Principles 
and Practice. 5th ed: Churchill Livingstone; 2009.
Wahl S, Vichinsky E. Pulmonary hypertension in hemolytic anemias. 
F1000 Med Rep 2010;2:10.
Zhang Y, Qui Y, Zhu J, Gao D. Pulmonary hypertension associated 
with autoimmune hemolytic anemia: A case report. International 
Journal of Cardiology 2007;115:E1-E2.
Singh S, Sharma S. High-output cardiac failure. StatPearls 2020.
Haw A, Palevsky HI. Pulmonary hypertension in chronic hemolytic 
anemias: Pathophysiology and treatment. Respiratory Medicine 
2018;137:191-200.
Prins KW, Thenappan T, Weir EK, Kalra R, Pritzker M, Archer SL. 
Repurposing medications for treatment of pulmonary arterial 
hypertension: what's old is new again. Journal of the American 
Heart Association 2019;8:e011343.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Lorem ipsum
